CClinicalTrials.gg
CompletedNCT04885933Updated May 13, 2021

The Impact of Sarcopenia on COPD Exacerbation Admission Outcome and Further Exacerbation Risk

An observational study in Sarcopenia and COPD Exacerbation, sponsored by Far Eastern Memorial Hospital. Completed at 1 site in Taiwan. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Far Eastern Memorial Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
43
Ages
45 Years and older
Sex
All
01

Study summary

Chronic obstructive pulmonary disease (COPD) is more prevalent and has more impact on health status because of progressive air pollution, tobacco smoking and aging society. The COPD prevalence investigation in 2013 by phone call showed at least 6% of the population with more than 40 years-old in Taiwan. It also was the 7th ranking of death causes in Taiwan then. Apart from chronic inflammation in lung and deteriorated lung function, it had extrapulmonary complications, such as cardiovascular problems, osteoporosis and muscle wasting. The concept of sarcopenia was proposed at first in 1989. It increases the risk of falls, disability and lowering life quality. Besides, it increased the mortality risk after admission from acute ward. Thereafter, sarcopenia is one of COPD co-morbidities, which should have great impacts of COPD. The studies showed sarcopenia reduced exercise capacities and worsening dyspnea scores. On the other hand, COPD exacerbation brings significant health burden. But there is limited data about the effect on sarcopenia on COPD exacerbation. We conducted a prospective observational study. We measured skeletal muscle mass and the strength of the used hand grip within 3 days of admission and before discharge. Mortality and exacerbation in one year are the primary end-points

02

Conditions studied

  • Sarcopenia
  • COPD Exacerbation
03

In context

Pulmonary Disease, Chronic Obstructive

4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.

This study's enrollment of 43 is below the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Far Eastern Memorial Hospital is the lead sponsor of 253 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients more than 45 years-old, were admitted due to COPD exacerbation.

Eligibility criteria

Inclusion criteria: Patients more than 45 years-old, were admitted due to COPD exacerbation.

COPD exacerbation criteria:

  1. acute worsening respiratory symptoms without any other causes, And
  2. Smoking more than 15 pack-years or the history of noxious gas exposure, And
  3. Spirometry reports suggests obstructive ventilatory defect (FEV1/FVC \<0.7) or
  4. Attending physicians diagnose as COPD by clinical parameters if spirometry data are not available while enrolling.

Definite COPD exacerbation: fulfill 1、2、3 Probable COPD exacerbation: fulfill 1、2、4

Exclusion criteria:

  1. Significant fluid retention such as edema, pleural effusion or ascites,
  2. Patients with permanent pacemaker or implantable cardioverter defibrillator ,
  3. Morbid obesity with BMI >34
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
43 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • COPD exacerbation

    Diagnostic Test: sarcopenia measurement

Interventions

  • Diagnostic testsarcopenia measurement

    BIA for fat free muscle mass hand grasp strength

06

What researchers measure

Primary outcomes

  1. Mortality and exacerbations within 1 year of admission

    Time frame: 1 years

07

Study locations

1 site
  • Far Eastern Memorial Hospital
    New Taipei, 220, Taiwan
08

References and documents

Publications

  • Lee CT, Wang PH. Handgrip strength during admission for COPD exacerbation: impact on further exacerbation risk. BMC Pulm Med. 2021 Jul 21;21(1):245. doi: 10.1186/s12890-021-01610-7. PubMed 34289815 ↗

Individual participant data

Plan to share: No — The data that support the findings of this study are available from the corresponding author, \[P.H.W\], upon reasonable request

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04885933
Lead sponsor
Far Eastern Memorial Hospital
Responsible party
Sponsor
First posted
May 13, 2021
Start date
Jan 31, 2018
Primary completion
Jan 31, 2019
Completion
Jun 21, 2020
Last update
May 13, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion